生命科学资讯

Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and more

FDA says it explained issues early on for Corcept's rejected Cushing's syndrome drug

Bitterroot reverts to preclinical biotech in CD47 as CEO leaves

CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshild

Ultragenyx resubmits gene therapy for rare neuro disease to FDA

Quince's steroid therapy for rare disease fails, shares tank

Janux hires CMO after T cell engager deal with Bristol Myers; A batch of appointments at Lexeo

Reed Jobs' cancer biotech investment firm Yosemite eyes $350M fund

AstraZeneca pays $1.2B for CSPC's long-acting obesity drugs

Takeda 'anticipated' Medicare negotiations for top seller Entyvio

Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says

White House postpones planned TrumpRx launch event

Sanofi vows to stay committed to vaccines as portfolio takes a hit

The disrupted fate of pharmacy startups

Sanofi's pipeline cuts; Breakthru Medicine raises $60M

Summit gets November PDUFA date for its PD-1xVEGF bispecific

Trump looks to raise South Korea levies; Siegfried expands

Agomab anticipates $182M IPO as it builds fibrosis pipeline

AstraZeneca makes $15B bet on China to expand manufacturing and R&D

Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff